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OBJECTIVE: Adenosine deaminase acts on adenosine and deoxyadenosine metabolism and modulates the immune
response. The adenosine deaminase G22A polymorphism (20q.11.33) influences the level of adenosine deaminase
enzyme expression, which seems to play a key role in maintaining pregnancy. The adenosine deaminase 2
phenotype has been associated with a protective effect against recurrent spontaneous abortions in European
Caucasian women. The aim of this study was to investigate whether the G22A polymorphism of the adenosine
deaminase gene is associated with recurrent spontaneous abortions in Brazilian women.
METHODS: A total of 311 women were recruited to form two groups: G1, with a history of recurrent spontaneous
abortions (N=129), and G2, without a history of abortions (N=182). Genomic DNA was extracted from peripheral
blood with a commercial kit and PCR-RFLP analysis was used to identify the G22A genetic polymorphism. Fisher’s
exact test and odds ratio values were used to compare the proportions of adenosine deaminase genotypes and
alleles between women with and without a history of recurrent spontaneous abortion (p,0.05). The differences
between mean values for categorical data were calculated using unpaired t tests. The Hardy-Weinberg equilibrium
was assessed with a chi-square test.
RESULTS: Statistically significant differences were identified for the frequencies of adenosine deaminase genotypes
and alleles between the G1 and G2 groups when adjusted for maternal age.
CONCLUSIONS: The results suggest that the adenosine deaminase *2 allele is associated with a low risk for recurrent
spontaneous abortions, but this association is dependent on older age.
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INTRODUCTION
Recurrent spontaneous abortion (RSA) is defined by two
or more consecutive miscarriages before 20 weeks of
gestation.1,2 The etiology of RSA is varied, but immunolo-
gical, anatomical, endocrine, and genetic aspects are
considered the most important factors. These factors may
act on fetus selection in such a way as to impede the
implantation of the zygote or to prevent fertilization.3
The enzyme adenosine deaminase (ADA; EC 3.5.4.4)
catalyzes the deamination of adenosine and deoxyadeno-
sine, thereby affecting the methylation process, cell growth
and differentiation, apoptosis, DNA replication and
immune functions.4,5 The genetic deficiency of ADA in
humans results in severe combined immunodeficiency
syndrome (SCID) of both the humoral and cellular immune
responses.6 The polymorphism of the ADA gene (20q13.11)
resulting from the substitution of G by A at nucleotide 22 of
exon 1 replaces the Asp amino acid (ADA*1 allele) with Asn
(ADA*2 allele) amino acid in position 8 of the enzyme.
Consequently, individuals with the ADA*2 allele express
low levels of ADA compared to homozygous ADA*1/*1
individuals.7
ADA activity is critical in maintaining a normal preg-
nancy.8,9 In a previous report, Nicotra et al.10 observed that
the frequency of the ADA*2 allele is lower in European
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women who suffer RSA than those who do not, suggesting a
protective effect of this allele against RSA and higher
fertility rates among women with ADA*2 allele. Recently,
these same authors observed a synergic effect of ACP1 (low
molecular weight protein tyrosine phosphatase) and ADA
polymorphisms with respect to RSA.11 These authors
concluded that women with high ADA activity and low
ACP1 activity have a higher susceptibility to RSA. A
European ethnic background is present in the Brazilian
population,12 but data are scarce on the importance of the
ADA G22A genetic polymorphism in RSA in Brazilian
women. The aim of this study was to investigate whether
the ADA G22A polymorphism is associated with RSA in
Brazilian women.
PATIENTS AND METHODS
Ethical considerations
This study was approved by the Research Ethics
Committee of the Medical School in Sa˜o Jose´ do Rio Preto
- FAMERP (# 308/2008). The objectives of the investigation
and all procedures performed in the study were explained
to selected patients, and those who agreed to participate in
the study gave their written consent.
Patient selection
Two groups of pregnant women were selected from the
Gynecology and Obstetrics Clinic, Hospital de Base from the
Regional Medical School Foundation in Sa˜o Jose´ do Rio
Preto, Sa˜o Paulo State, Brazil. The first group (G1, N = 129)
included only women who had suffered at least two
consecutive spontaneous abortions with the same partner
according to their medical records and to reports from the
patients themselves. The second group (G2, N = 182)
included only women with at least two successive sponta-
neously conceived pregnancies and no history of sponta-
neous abortion. Patients who were younger than 18 years
old were excluded from the study.
Data collection
An epidemiological questionnaire was completed by all
participating patients, and these data were later confirmed
with their medical records. Comorbidities such as a history
of diabetes, hypertension, polycystic ovarian syndrome,
uterine malformation, antiphospholipid antibodies, and
endometriosis were also collected from the medical records.
Collection of blood samples and genomic DNA
extraction
Five milliliters of peripheral blood was collected from
each participant in tubes containing EDTA anticoagulant.
Genomic DNA was extracted from 200 mL of whole blood
using a commercial kit (PureLinkTM Genomic DNA Mini
Kit, Invitrogen). The manufacturer’s instructions were
strictly followed.
Identification of the ADA*1 and ADA*2 alleles
The identification of the ADA*1 and ADA*2 alleles was
achieved using PCR-RFLP analysis following the protocol of
Safranow et al.13 A gene amplification reaction (25 mL final
volume) was performed for each sample of genomic DNA
under the following conditions: 7.2 mL of MilliQ water, 5.0 mL
of PCR Buffer Green (5x, Promega), 1.5 mL MgCl2 (25 mM,
Promega), 2.1 mL of DMSO (Nuclear), 1.0 mL of 2-mercapto-
ethanol (200 mM, Vetec), 1.0 mL of sense primer (5 pM, IDT;
59-GCCCGGCCCGTTAAGAAGAGC-39), 1.0 mL of antisense
primer (5 pM, IDT; 59- GGTCAAGTCAGGGGCAG-
AAGCAGA-39), 4.0 mL of dNTPs (1.25 mM, Invitrogen),
0.2 mL of GoTaq Hot Start DNA polymerase (5 U,
Promega), and 2.0 mL of genomic DNA. As an internal
contamination control, a tube was prepared under identical
conditions but without the genomic DNA (blank). The
amplification conditions were as follows: 94 C˚ for 15 minutes,
36 cycles of 94 C˚ for 40 seconds, 66 C˚ for 80 seconds, 72 C˚ for
80 seconds, and 1 cycle of 72 C˚ for 8 min, with the product
remaining at 4 C˚ ad infinitum. The amplified 397 bp
fragment was analyzed by 2% agarose gel electrophoresis
(Invitrogen) and ethidium bromide staining (Invitrogen). The
PCR product (7.0 mL) was incubated at 65 C˚ with 0.7 mL of
Taq I Fast Digest (1 U, Fermentas) and 1.34 mL of enzyme
buffer (10x, Fermentas) for 20 minutes. After an electrophor-
esis run of 30 minutes at 100 volts in 2% agarose gel
(Invitrogen), the fragments were viewed using ethidium
bromide staining. The PCR product corresponding to the
ADA*1 allele (G22) was then cleaved into two fragments: a
245 bp fragment and a 152 bp fragment. The ADA*2 allele
(22A) was identified by the absence of the Taq I restriction
site.
Statistical analysis
The GraphPad Instat computer program version 3.06 was
used for all statistical calculations. Fisher’s exact test was
used to detect differences in the distribution of ADA
genotypes and alleles with respect to RSA; a 5% alpha error
was considered acceptable. The differences between mean
values for categorical data were calculated by the unpaired t
test. Odds ratios and 95% confidence intervals were also
calculated. The chi-square test was applied to compare the
overall frequencies of ADA genotypes and verify whether
the distribution of the ADA genotypes was in Hardy-
Weinberg equilibrium using the Online Encyclopedia for
Genetic Epidemiology studies (OEGE) (http://www.oege.
org/software/hwe-mr-calc.shtml).
RESULTS
This study evaluated women with (G1) and without (G2)
a history of RSA. There were statistically significant
differences with respect to the mean age (G1: 31.9¡5.7 vs.
G2: 29.2¡5.8; p= 0.0001) and average number of pregnan-
cies (G1: 4.6¡1.5 vs. G2: 3.5¡0.9; p= 0.0001). The mean
number of spontaneous abortions in G1 was 2.7 (¡0.8),
ranging from 2 to 6, and the average numbers of live births
in G1 and G2 were 0.5 (¡0.3) and 2.6 (¡1.0), respectively
(p= 0.0001).
The identification of ADA genotypes was accomplished
based on the electrophoretic profile of the 397 bp fragment
of exon 1 of the ADA gene after digestion with the Taq I
enzyme (Figure 1). The ADA*1/*1 and ADA*1/*2 genotypes
were found in G1 and G2, but just one patient with the
ADA*2/*2 genotype was observed in G2 (Table 1). The
distributions of the ADA genotypes were found to be in
Hardy-Weinberg equilibrium in G1 (x2 = 0.26, DF 1) and G2
(x2 = 0.57, DF 1). The frequencies of the ADA*1/*1, ADA*1/*2
and ADA*2/*2 genotypes were similar and showed no
statistically significant differences (p= 0.6771, x2 = 0.78; DF
2). The differences remained insignificant even when the
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comparison between G1 and G2 was restricted to the
ADA*1/*2 and ADA*2/*2 genotypes (p= 0.8342, OR = 1.177,
95% CI = 0.536-2.586). Although the frequencies of the
ADA*1 and ADA*2 alleles were different in G1 and G2,
the difference was not statistically significant (p= 0.7050,
OR: 1.237, 95% CI: 0.578-2.646).
A comparative analysis of the frequencies of the ADA*1
and ADA*2 alleles when controlling for age revealed
statistically significant differences between the G1 and G2
groups (Table 2).
The data for G1, grouped according to the ADA
genotypes (ADA*1/*1 and ADA*1/*2), are shown in Table 3.
There were no statistically significant differences in the
mean age, average number of pregnancies, number of live
births or comorbidities between women with the ADA*1/*1
genotype and those with the ADA*1/*2 genotype.
Controlling for comorbidities, these analyses were not
statistically significant (diabetes: OR: 0.385, CI 95%: 0.045-
3.297, p= 0.3601; hypertension: OR: 1.817, CI 95%: 0.235-
14.017, p= 1.000; polycystic ovarian syndrome: OR: 4.120, CI
95%: 0.243-69.710, p= 0.3984; uterine malformation: OR:
1.411, CI 95%: 0.080-24.737, p= 1.000; antiphospholipid
antibodies: OR: 1.046, CI 95%: 0.132-8.241, p= 1.000; endo-
metriosis: OR: 0.569, CI 95%: 0.159-2.031, p= 0.4198).
DISCUSSION
The aim of this study was to investigate the association
between the G22A polymorphism of the ADA gene in
Brazilian women with a history of RSA. Because much of
the Brazilian population has a clear European ancestry,12 we
postulated that the ADA G22A genetic polymorphism might
be associated with RSA in Brazilian women. The series of
this study is representative of the population of the
northwestern region of Sa˜o Paulo State, which is chiefly
composed of Italian, Spanish, Portuguese, and African
descendants.14 To avoid possible bias, a control group was
formed of women who had at least two successful
pregnancies and no history of miscarriages.
The women who had experienced RSA who were
enrolled in this study (G1) had a higher mean age compared
to those who had not (G2). This difference may result from
the fact that women without risk factors for spontaneous
abortions achieve reproductive success and their desired
number of children at an earlier age, whereas women with
reproductive problems are encouraged to persist longer in
their attempts to conceive and reproduce.15 Moreover, older
age is a risk factor for RSA.1,3 This observation is supported
by data from a recent demographic survey carried out in
Brazil, which showed that maternal age of higher than 35
years contributes to an increased prevalence of RSA.16
In the present study, women who had experienced RSA
became pregnant a significantly higher number of times
than those who had not. Spontaneous abortions were
confirmed based on clinically recognized pregnancy losses
before 20 weeks of gestation; this condition has great
predictive value for establishing the occurrence of unsuc-
cessful pregnancies.1,3 Women who experience RSA persist
in attempts to become pregnant even if the pregnancy does
not often reach full term. Moreover, there is evidence that
some early fetal losses are not clinically recognized in
women with a predisposition to RSA because these
pregnancies do not last long enough to be characterized as
such. These fetal losses are not included in the statistics, and
the rate of spontaneous abortions is therefore underesti-
mated.17
Several women in G1 gave birth to live babies, but the
average number of births was lower than those in G2. This
finding is consistent with the finding that women at low risk
for RSA are more likely to produce children. Moreover, in
women at risk for RSA, the chance of spontaneous abortions
increases with each fetal loss.18,19 It seems that reproductive
success is achieved at a younger age, especially when
mothers have no risk factors for RSA, contributing to a
greater number of live births in this group.16,19
The frequencies of ADA genotypes and the ADA*1 and
ADA*2 alleles were similar between G1 and G2 and were
not associated with the occurrence of RSA. Hence, from a
preliminary overview, the results presented in this study are
different from those observed for Italian women in whom
Figure 1 - The electrophoretic profile of the fragment of 397 base
pairs (bp) of exon 1 of the ADA gene after digestion with the Taq
I enzyme showing the ADA*1/*1 (1), ADA*1/*2 (2) and ADA*2/*2
(3) genotypes and the marker (L) of 100 base pairs.
Table 1 - The frequencies of ADA genotypes and alleles in women with (G1) and without (G2) a history of recurrent
spontaneous abortions.
G1 (N=129) G2 (N=182) OR* CI 95% p-value**
ADA genotypes N % N %
ADA*1/*1 118 91.5 164 90.2 1.177 0.536 – 2.586 0.8435
ADA*1/*2 11 8.5 17 9.3 0.904 0.408 – 2.003 0.8436
ADA*2/*2 0 0.0 1 0.5 0.426 0.017 – 10.552 1.0000
Alleles
ADA*1 247 95.7 345 94.8 1.237 0.578 – 2.646 0.7050
ADA*2 11 4.3 19 5.2
*Unadjusted odds ratio.
**Calculated by Fisher’s exact test.
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the ADA*2 allele was associated with a lower risk of
RSA.10,11
Different factors may contribute to the differences
observed. It is possible that the ADA*2 allele has a low
frequency in the Brazilian female population as a result of
ethnic mixing and that its protective effect is overshadowed
by other determinants of RSA. In fact, population analysis
revealed that the frequency of the ADA*2 allele is 0.12 in
Caucasians and varies between 0.03 and 0.04 in African
descendants.7,20 The frequencies of the ADA*2 allele found
in both groups of this study were lower than those reported
for Caucasians but very close to those observed in African
descendants. Because much of the population of
the northwestern region of Sa˜o Paulo State has African
ancestry,14 this characteristic could contribute to the
reduced frequency of the ADA*2 allele in the casuistic
analyzed in this study.
The frequency of the ADA G22A genetic polymorphism in
different Brazilian regions has been little explored. A recent
study found that the frequency of the ADA*2 allele in
healthy men and women in the State of Rio Grande do Sul is
11.7%.21 This percentage is approximately twice that found
in the present study, but the ethnic background of the
population of southern Brazil is different from that of the
northwestern region of Sa˜o Paulo State.14,22,23 It is possible
that the frequency of the ADA*2 allele among Brazilians is
influenced by ethnic and racial admixture. Investigations
focusing the ADA G22A polymorphism in other regions of
Brazil could confirm this proposition.
The ADA genotypes and alleles were compared between
the G1 and G2 groups when controlling for maternal age
because this variable was found to be associated with the
risk for RSA. The results did not reveal statistically
significant differences in the frequency of the ADA*2 allele
among those aged 35 years or younger, whereas an
association between this allele and low risk for RSA was
observed for women older than 35 years of age.
The role of the ADA*2 allele in reducing the risk of RSA is
not completely understood. The presence of an ADA*2 allele
reduces ADA enzyme expression to between 15 and 20% of
that found in the homozygous ADA*1/*1 genotype, which
enables an increase in adenosine levels.7 Consequently,
carriers of at least one ADA*2 allele have higher levels of
circulating and intracellular adenosine.24
Because adenosine acts as a hormone that regulates blood
flow, neurotransmission and platelet aggregation and is a
potent vasodilator,25,26 its presence in the uterus and the
placenta could contribute to a reduced rate of early loss of
zygotes or fetuses, thus protecting ADA*2-carrying women
against RSA.10,11 This protection may be especially relevant
for women older than 35 years of age. Additionally, the
increased adenosine resulting from the ADA*2 allele could
contribute to vascular integrity, thus increasing uterine and
placental blood flow.9 Therefore, evaluations of ADA levels
at different times during the gestational period among
women carrying distinct ADA genotypes could help to
clarify the potential effects of the ADA*2 allele during
successful pregnancies and shed additional light on the
biological and clinical impact of this enzyme on RSA and in
assisted reproduction.
Different studies have observed low frequencies of the
ADA*2 allele in couples with sterility problems, women
suffering from RSA, those with great variability in gestation
time and those who have low birth weight newborns.10,11
Because this enzyme has an important role in modulating
the immune response, a reduction in its expression seems to
affect the fertility rate of women older than 35 years of age.
To assess the differential effects of the ADA*1 and ADA*2
alleles on miscarriages, the comorbidities of pregnant
women in G1 with the ADA*1/*1 and ADA*1/*2 genotypes
were compared. There were no statistically significant
differences in mean age, the average numbers of pregnan-
cies and spontaneous abortions, the average number of live
births, diabetes (including pregnancy-related and type II
diabetes), hypertension, polycystic ovarian syndrome, uter-
ine malformations, antiphospholipid antibodies or endome-
triosis. Therefore, the ADA*1 and ADA*2 alleles, when
controlled for comorbidities, are not associated with the
presence or absence of RSA. These comorbidities are
associated with miscarriages, but their influence may be
independent of the ADA alleles and genotypes.
The small number of ADA*1/*2 women in G1, which
reduces the power of the test, does not allow an analysis of
whether either allele provides a biological advantage with
Table 2 - A comparison of the frequencies of ADA alleles and genotypes in women with (G1) and without (G2) RSA aged
35 years or younger and those older than 35 years of age.
Genotypes G1 (N=129) G2 (N=182)
35 or younger N=85 % N=155 % OR* CI 95% p-value**
ADA*1/*1 76 89.4 146 94.2 0.5205 0.198 – 1.366 0.2042
ADA*1/*2 9 10.6 9 5.8
Alleles
ADA*1 161 94.7 301 97.1 0.5349 0.208 – 1.374 0.2126
ADA*2 9 5.3 9 2.9
Older than 35 (N=44) % (N=27)
ADA*1/*1 42 95.5 18 66.7 10.500 2.059 – 53.539 0.0019
ADA*1/*2 2 4.5 8 29.6 0.1131 0.021 – 0.584 0.0050
ADA*2/*2 0 0.0 1 3.7 0.1985 0.007 – 5.055 0.3803
Alleles
ADA*1 86 97.7 44 81.5 9.773 2.051 – 46.573 0.0012
ADA*2 2 2.3 10 18.5
*Adjusted odds ratio.
** ACalculated by Fisher’s exact test.
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respect to early fetal loss as established by other determi-
nants of RSA.
In summary, the data of this study show that the risk for
RSA increases with maternal age and that the ADA*2 allele
of the ADA gene is associated with low risk of RSA among
older women.
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Live births (SD) 0.7 (¡0.5) 0.5 (¡0.3) 0.1953
Miscarriages (SD) 2.7 (¡0.8) 2.5 (¡0.6) 0.6765
Comorbidities N % N % p-value **
Diabetes 3 1.9 1 9.1 0.3030
Hypertension 16 13.3 1 9.1 1.0000
Polycystic ovarian syndrome 18 15.2 0 0.0 0.3607
Uterine malformation 6 2.8 0 0.0 1.0000
Antiphospholipid antibodies 9 8.5 1 9.1 1.0000
Endometriosis 14 9.5 3 27.3 0.1602
*Calculated by an unpaired t test.
**Calculated by Fisher’s exact test.
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